KEN SHE Study on HPV-vaccine Efficacy

November 22, 2021

Dose of Hope

KEMRI Twitter

Single-dose HPV vaccine highly effective, researchers say

Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide. Read More

New findings show that a single dose of the HPV vaccine is highly effective compared to the 3-dose

New findings show that a single dose of the HPV vaccine is highly effective compared to the 3-dose regimen administered to women.

November 21, 2021

Hope as trial shows single dose of vaccine is highly effective

Hope as trial shows single dose of vaccine is highly effective Cancer of the cervix a leading cause of cancer deaths among women Trial for HPV vaccine took place between Dec. 2018 and June 2021 Women above 18 years in Kenya get 3 doses of HPV vaccine.

September 21, 2019

Started Enrolling, Dec 2018

Enrollment is anticipated to take 12 months and recruitment will be completed by January 2020. For more information about the status of the study, please view the ClinicalTrials.gov page on The KEN SHE Study on HPV-vaccine Efficacy: https://clinicaltrials.gov/ct2/show/study/NCT03675256

Aug 7, Kenya Research Training Center (KRTC) Seminar: The KEN SHE Study

Presentation by Dr. Ruanne Barnabas, Protocol Chair of The KEN SHE Study, for the August 7, 2019 Kenya Research Training Center (KRTC) seminar.